Drug Target Investigation of --Coumaroyl-'-Caffeoylputrescine, a Naturally-Occurring Alkaloid Derived from

Overview

Journal Antioxidants (Basel)

Date 2025 Jan 25

PMID 39857345

Authors

Chuang Liu

Jun Dang

Minchen Wu

Affiliations

Soon will be listed here.

Abstract

The exploration of drug targets has always been a priority in new drug research, and this work is even more essential for natural active compounds. is a traditional Tibetan medicine with excellent antioxidant properties. In this study, an alkaloid, --coumaroyl-'-caffeoylputrescine (PCC), was first isolated from the plant, , with a DPPH scavenging rate of 0.936 μg/mL. To further identify its target, the drug affinity responsive target stability technique and multiple public databases were integrated to retrieve a total of 317 common targets from comprehensive screening. A further bioinformatics analysis not only identified 13 hub targets but also indicated PCC as having biological activities against cancer and affecting metabolic diseases. Integrating reverse virtual docking, molecular dynamics simulations, and cellular thermal shift assays ultimately focused on HSP90AA1 as the target of PCC. An in vitro study on liver (HepG2) cells and breast (MCF-7) cancer cells revealed that PCC modulates HSP90AA1, subsequently affecting Mut-p53 expression, triggering a cascade effect that reduced adriamycin-induced drug resistance in cells. Furthermore, a prediction of the absorption, distribution, metabolism, excretion, and toxicity was also applied to evaluate the drug-like properties of PCC. Overall, the integrated strategy used in this study successfully identified the target of PCC, providing a valuable paradigm for future research on the action targets of natural products.

References

Aviles-Alia A, Zulaica J, Perez J, Rubio-Martinez J, Geller R, Granadino-Roldan J . The Discovery of inhibitors of the SARS-CoV-2 S protein through computational drug repurposing. Comput Biol Med. 2024; 171:108163. DOI: 10.1016/j.compbiomed.2024.108163. View

Zhang M, Peng Y, Yang Z, Zhang H, Xu C, Liu L . DAB2IP down-regulates HSP90AA1 to inhibit the malignant biological behaviors of colorectal cancer. BMC Cancer. 2022; 22(1):561. PMC: 9118737. DOI: 10.1186/s12885-022-09596-z. View

Park M, Jung E, Park J, Park S, Ko D, Seo J . The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics. 2024; 14(6):2442-2463. PMC: 11024854. DOI: 10.7150/thno.93236. View

Mao X, Xu H, Li S, Su J, Li W, Guo Q . Exploring pharmacological mechanisms of Xueshuan-Xinmai-Ning tablets acting on coronary heart disease based on drug target-disease gene interaction network. Phytomedicine. 2019; 54:159-168. DOI: 10.1016/j.phymed.2018.09.018. View

Yang S, Nie T, She H, Tao K, Lu F, Hu Y . Regulation of TFEB nuclear localization by HSP90AA1 promotes autophagy and longevity. Autophagy. 2022; 19(3):822-838. PMC: 9980472. DOI: 10.1080/15548627.2022.2105561. View

Reynolds T, Blagg B . Extracellular heat shock protein 90 alpha (eHsp90α)'s role in cancer progression and the development of therapeutic strategies. Eur J Med Chem. 2024; 277:116736. PMC: 11374465. DOI: 10.1016/j.ejmech.2024.116736. View

Masoudi-Sobhanzadeh Y, Omidi Y, Amanlou M, Masoudi-Nejad A . Drug databases and their contributions to drug repurposing. Genomics. 2019; 112(2):1087-1095. DOI: 10.1016/j.ygeno.2019.06.021. View

Davodabadi F, Sajjadi S, Sarhadi M, Mirghasemi S, Nadali Hezaveh M, Khosravi S . Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery. Eur J Pharmacol. 2023; 958:176013. DOI: 10.1016/j.ejphar.2023.176013. View

Agamah F, Mazandu G, Hassan R, Bope C, Thomford N, Ghansah A . Computational/in silico methods in drug target and lead prediction. Brief Bioinform. 2019; 21(5):1663-1675. PMC: 7673338. DOI: 10.1093/bib/bbz103. View

10.

Kopecka J, Trouillas P, cipak Gasparovic A, Gazzano E, Assaraf Y, Riganti C . Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets. Drug Resist Updat. 2019; 49:100670. DOI: 10.1016/j.drup.2019.100670. View

11.

Pletscher-Frankild S, Palleja A, Tsafou K, Binder J, Jensen L . DISEASES: text mining and data integration of disease-gene associations. Methods. 2014; 74:83-9. DOI: 10.1016/j.ymeth.2014.11.020. View

12.

Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X . PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017; 45(W1):W356-W360. PMC: 5793840. DOI: 10.1093/nar/gkx374. View

13.

Daina A, Zoete V . Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. Commun Chem. 2024; 7(1):105. PMC: 11082207. DOI: 10.1038/s42004-024-01179-2. View

14.

Sherman B, Hao M, Qiu J, Jiao X, Baseler M, Lane H . DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022; 50(W1):W216-W221. PMC: 9252805. DOI: 10.1093/nar/gkac194. View

15.

Muriithi W, Wanjiku Macharia L, Pilotto Heming C, Echevarria J, Nyachieo A, Niemeyer Filho P . ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biol Med. 2020; 17(2):253-269. PMC: 7309456. DOI: 10.20892/j.issn.2095-3941.2019.0284. View

16.

Yang L, Bui L, Hanjaya-Putra D, Bruening M . Membrane-Based Affinity Purification to Identify Target Proteins of a Small-Molecule Drug. Anal Chem. 2020; 92(17):11912-11920. DOI: 10.1021/acs.analchem.0c02316. View

17.

Westermaier Y, Barril X, Scapozza L . Virtual screening: an in silico tool for interlacing the chemical universe with the proteome. Methods. 2014; 71:44-57. DOI: 10.1016/j.ymeth.2014.08.001. View

18.

Twilley D, Rademan S, Lall N . A review on traditionally used South African medicinal plants, their secondary metabolites and their potential development into anticancer agents. J Ethnopharmacol. 2020; 261:113101. DOI: 10.1016/j.jep.2020.113101. View

19.

Lomenick B, Hao R, Jonai N, Chin R, Aghajan M, Warburton S . Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A. 2009; 106(51):21984-9. PMC: 2789755. DOI: 10.1073/pnas.0910040106. View

20.

Nickel J, Gohlke B, Erehman J, Banerjee P, Rong W, Goede A . SuperPred: update on drug classification and target prediction. Nucleic Acids Res. 2014; 42(Web Server issue):W26-31. PMC: 4086135. DOI: 10.1093/nar/gku477. View